Hot Topics in Diabetes: the future of antidiabetics in Australia ReportsnReports.com adds Datamonitor’s “Hot Topics in Diabetes: the future of antidiabetics in Australia” to its store.
REPORT SUMMARY THE DIAGNOSED DIABETIC POPULATION IN AUSTRALIA IS GROWING, AND PATIENTS ARE CONTINUING TO STRUGGLE TO REACH AND MAINTAIN TARGET BLOOD GLUCOSE LEVELS. THESE MARKET DRIVERS, COMBINED WITH A PREPONDERANCE OF SAFETY CONCERNS OVER CURRENTLY MARKETED ANTIDIABETICS IN RECENT YEARS, MEANS THAT THE OPPORTUNITY FOR NEW AND IMPROVED PIPELINE CANDIDATES IS LUCRATIVE. FEATURES AND BENEFITS
PROVIDES INSIGHT INTO THE KEY DRIVERS AND RESISTORS TO ANTIDIABETIC DRUG UPTAKE IN AUSTRALIA
ANALYZES THE CURRENT DIABETES TREATMENT PARADIGM IN AUSTRALIA
ASSESSES KEY BRANDS IN THE INSULIN AND NON-INSULIN ANTIDIABETICS MARKET IN AUSTRALIA
SUMMARIZES KEY PIPELINE CANDIDATES EXPECTED TO LAUNCH IN AUSTRALIA, AND THEIR LIKELY IMPACTS HIGHLIGHTS DESPITE STRONG MARKET DRIVERS, THE AUSTRALIAN ANTIDIABETICS MARKET CAN BE DIFFICULT TO PENETRATE, WITH A NUMBER OF LEADING GLOBAL BRANDS FACING RESTRICTIONS IN APPROVED INDICATIONS AND DIFFICULTIES OBTAINING REIMBURSEMENT. WITH LIMITED PIPELINE DEVELOPMENT IN THE INSULIN CLASS, THE MAJOR IMPACT ON GROWTH WILL COME FROM THE BIOSIMILAR THREAT, EXPECTED TO TAKE EFFECT IN AUSTRALIA FROM 2015. MEANWHILE, GLUCAGON-LIKE PEPTIDE-1 WILL PICK UP MARKET SHARE IF REIMBURSEMENT DIFFICULTIES CAN BE RESOLVED AND AS LONGER-ACTING MOLECULES REACH THE AUSTRALIAN MARKET. ORAL ANTIDIABETICS WILL CONTINUE TO PROSPER, DRIVEN BY A NUMBER OF LATE-STAGE PIPELINE CANDIDATES, INCLUDING A NEW CLASS OF SODIUM-DEPENDENT GLUCOSE TRANSPORTER-2 INHIBITORS. HOWEVER, THE THIAZOLIDINEDIONE CLASS IS EXPECTED TO LOSE MARKET SHARE TO OTHER ORAL ANTIDIABETICS WITH BETTER LONG-TERM SAFETY PROFILES. TABLE OF CONTENTS
OVERVIEW CATALYST EXECUTIVE SUMMARY STRATEGIC SCOPING AND FOCUS DATAMONITOR KEY FINDINGS RELATED REPORTS OVERVIEW OF DIABETES IN AUSTRALIA AUSTRALIA-SPECIFIC DIABETES EPIDEMIOLOGY TYPE 1 DIABETES IS INCREASING IN INCIDENCE, BUT OVERALL PREVALENCE REMAINS LOW TYPE 2 DIABETES IS HIGHLY PREVALENT IN AUSTRALIA AUSTRALIAN DIABETES MARKET DRIVERS THE PREVALENCE OF DIABETES IS INCREASING IN AUSTRALIA HALF OF ALL AUSTRALIAN DIABETES PATIENTS DO NOT REACH HBA1C TARGET OF <7% THE AUSTRALIAN GOVERNMENT HAS COMMITTED SIGNIFICANT FUNDS TO DIABETES RESEARCH AND MANAGEMENT LAUNCH OF NOVEL COMPOUNDS WILL STIMULATE THE NON-INSULIN MARKET AUSTRALIAN DIABETES MARKET RESISTORS NOVEL DRUGS MAY STRUGGLE TO GAIN PHARMACEUTICAL BENEFITS SCHEME LISTINGS BIOSIMILARS WILL BEGIN TO IMPACT INSULIN SALES ISSUES WITH SAFETY AND EFFICACY OF THIAZOLIDINEDIONES HAVE JADED SOME PRESCRIBERS HEALTH REFORMS AIM TO DECREASE THE DIABETES INCIDENCE AND SPENDING BY INCREASING PREVENTATIVE CARE AND CHRONIC DISEASE MANAGEMENT PROGRAMS STRATEGIES TO ACCESS THE AUSTRALIAN ANTIDIABETICS MARKET NOVO NORDISK IDENTIFIES ITSELF AS A DIABETES-FOCUSED COMPANY AND OFFERS SUPPORT SERVICES ELI LILLY NEEDS TO IMPROVE ITS DISSEMINATION OF PHYSICIAN AND PATIENT EDUCATION MERCK’S CAMPAIGN PROMOTING JANUVIA TO GPS ENSURED RAPID PRODUCT UPTAKE THE CURRENT DIABETES TREATMENT PARADIGM IN AUSTRALIA AUSTRALIAN DIABETES MANAGEMENT GUIDELINES DIABETES TREATMENT IN PRACTICE IN AUSTRALIA DRIVERS OF BRAND CHOICE PREFERRED TREATMENT OPTIONS FOR DIABETES IN AUSTRALIA UNMET NEEDS IN THE AUSTRALIAN DIABETES MARKET THE FUTURE OF DIABETES TREATMENT IN AUSTRALIA FUTURE TRENDS FOR CURRENT DIABETES BRANDS IN AUSTRALIA DRUG CLASSES AND BRANDS LOSING MARKET TRACTION DRUG CLASSES AND BRANDS WITH GROWTH POTENTIAL PIPELINE PRODUCTS LIKELY TO IMPACT THE AUSTRALIAN DIABETES MARKET ULTRA-LONG-ACTING INSULIN DEGLUDEC WILL OFFER PATIENTS DOSING BENEFITS THERE ARE MANY NEW GLP-1 AGONISTS IN LATE-STAGE DEVELOPMENT, DRIVING THE ANTIDIABETICS PIPELINE
ADDITIONAL DPP-4 INHIBITORS WILL FACE STRONGER COMPETITION, BUT STILL BENEFIT FROM FAVORABLE SAFETY PROFILES THE NEW SGLT-2 INHIBITOR CLASS IS EAGERLY AWAITED DUE TO WEIGHT-LOSS BENEFITS BIBLIOGRAPHY PUBLICATIONS AND ONLINE ARTICLES DATAMONITOR PRODUCTS APPENDIX CONTRIBUTING EXPERTS EXCHANGE RATES ASK AN ANALYST DATAMONITOR CONSULTING DISCLAIMER LIST OF TABLES TABLE: AUSTRALIA – PHARMACEUTICAL REIMBURSEMENT SCHEME STATISTICS ON INSULIN USAGE, 2010–11 TABLE: AUSTRALIA – PHARMACEUTICAL REIMBURSEMENT SCHEME STATISTICS ON BIGUANIDE AND SULFONYLUREA USAGE, 2010–11 TABLE: AUSTRALIA – PHARMACEUTICAL REIMBURSEMENT SCHEME STATISTICS ON THIAZOLIDINEDIONE USAGE, 2007/08–2010/11 TABLE: DURATION-4 BYDUREON (EXENATIDE LONG-ACTING RELEASE; AMYLIN/ELI LILLY) TRIAL TOP-LINE RESULTS TABLE: EXCHANGE RATES FROM US DOLLARS LIST OF FIGURS FIGURE: AUSTRALIA – TRENDS IN TOTAL INCIDENCE (PER 100,000) OF TYPE 1 DIABETES AMONG CHILDREN AGED 0–14, BY STATE AND TERRITORY OF RESIDENCE, 2010–20 FIGURE: AUSTRALIA – DIAGNOSED INCIDENT CASES OF TYPE 2 DIABETES FOR BOTH SEXES OF ALL AGES, 2010–20 FIGURE: AUSTRALIA – EXAMPLE OF MARKETING TO DIABETES PATIENTS IN CLINICS, 2011 FIGURE: AUSTRALIA – TREATMENT ALGORITHM FOR TYPE 2 DIABETES, 2011–12 FIGURE: AUSTRALIA – DRIVERS OF BRAND CHOICE IN THE ANTIDIABETICS MARKET, 2011 FIGURE: AUSTRALIA – ANTIDIABETICS EXPECTED TO LOSE MARKET SHARE OVER THE NEXT 5 YEARS, 2011 FIGURE: AUSTRALIA – ANTIDIABETICS EXPECTED TO GAIN MARKET SHARE OVER THE NEXT 5 YEARS, 2011 FIGURE: AUSTRALIA – INDICATIVE UPTAKE CURVES OF DIPEPTIDYL PEPTIDASE-IV INHIBITORS, 2008–11 FIGURE: AUSTRALIA – UPTAKE OF BYETTA (EXENATIDE; AMYLIN/ELI LILLY) COMPARED TO JANUVIA (SITAGLIPTIN; MERCK SHARP & DOHME) DURING FIRST 12 MONTHS, 2008–11 Latest Market Research Reports:
Data Center Rack Market in the EMEA region 2010-2014 Dental Implant Market in China 2010-2014
Digital Radiography Market in India 2010-2014 Geographical Information System Market in Europe 2010-2014 Global 3D Animation Software Market 2010-2014
About Us: ReportsnReports is an online library of over 100,000+ market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports. Follow us on Twitter: http://twitter.com/marketsreports Contact: Mr.Priyank 7557 Rambler road, Suite727,Dallas,TX75231 Tel: + 1 888 391 5441 E-mail: sales@reportsandreports.com http://www.reportsnreports.com Visit our Market Research Blog